The effect of beta-blockade on myocardial remodelling in Chagas' cardiomyopathy

Area of Science:

• Cardiology
• Infectious Diseases
• Pharmacology

Background:

• Chagas' disease, a parasitic infection prevalent in Latin America, affects approximately 30% of patients with cardiomyopathy.
• Severe cardiac damage and heart failure can develop in 10% of these patients.
• Beta-blockers are known to improve outcomes in heart failure, but their role in Chagas' cardiomyopathy is not well-defined.

Purpose of the Study:

• To evaluate the efficacy of carvedilol in mitigating cardiac remodeling and mortality in an animal model of Chagas' cardiomyopathy.
• To assess the impact of carvedilol on collagen accumulation in the myocardium.

Main Methods:

• A Syrian hamster model of Trypanosoma cruzi infection was utilized, with animals divided into control, infected, and infected + carvedilol groups.
• Echocardiography, electrocardiography, and myocardial morphometry (picrosirius red staining for collagen) were performed.
• Survival rates were monitored throughout the study period.

Main Results:

• Carvedilol did not significantly alter left ventricular dimensions or fractional shortening compared to the infected group.
• Significant collagen accumulation was observed in the interstitial and perivascular spaces of infected hamsters, which was not attenuated by carvedilol.
• While carvedilol did not improve overall survival, it demonstrated a mortality-reducing benefit during the acute phase (up to 100 days post-infection).

Conclusions:

• Carvedilol did not attenuate cardiac remodeling or long-term mortality in this Chagas' cardiomyopathy model.
• The study suggests a potential benefit of carvedilol in reducing mortality during the acute phase of Chagas' disease.
• Further research is warranted to explore the therapeutic potential of carvedilol in specific phases of Chagas' cardiomyopathy.